期刊
JOURNAL OF HEPATOLOGY
卷 58, 期 4, 页码 743-749出版社
ELSEVIER
DOI: 10.1016/j.jhep.2012.11.038
关键词
Toll-like receptor 9; Interferon; Hepatitis C virus; Liver; Oligonucleotide
资金
- Swiss National Science Foundation [320030_130243]
- Swiss National Science Foundation (SNF) [320030_130243] Funding Source: Swiss National Science Foundation (SNF)
Background & Aims: The toll-like receptor 9 (TLR9) agonist IMO-2125 is currently evaluated in clinical trials for chronic hepatitis C therapy. The aim of this study was to investigate the in vivo mode of action of a closely related compound, referred to as immunomodulatory oligonucleotide (IMO). Methods: We analyzed the Jak-STAT pathway activation and induction of interferon-stimulated genes in the liver of wild type, interferon-alpha/beta receptor-deficient and interferon-gamma-deficient mice, after administration of IMO. Results: IMO induced a prolonged activation of the Jak-STAT pathway and upregulation of interferon-stimulated genes in the mouse liver. Contrary to the response observed after interferon-alpha injection, the signalling induced by IMO was not abrogated following repeated administration. At early time points after IMO injection, STAT1 phosphorylation and interferon-stimulated gene induction required a functional interferon-alpha/beta receptor, whereas at the later time points, the activation was type I interferon-independent. Microarray analysis revealed that IMO induced a broad transcriptional response in the mouse liver. This included upregulation of cytokine and chemokine genes responsible for recruitment of IFN-gamma producers, such as T cells and natural killer cells. Interferon-gamma-deficient mice showed a transient response to IMO, demonstrating the central role of interferon-gamma in sustained activation of Jak-STAT pathway by IMO. Conclusions: The bimodal kinetics of response to IMO in the mouse liver are driven by the sequential endogenous production of type I and II interferons. The lack of refractoriness to IMO, combined with the long-lasting induction of interferon-stimulated genes, reveals a favourable pharmacodynamics profile of this novel TLR9 agonist for the treatment of chronic viral hepatitis. (C) 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据